Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 18 and 65 years of age~* Diagnosed with current PTSD as defined by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5),~* For patients with a qualifying Index trauma(s) resulting in PTSD that occurred during military service, military contractor, Department of Homeland Security or law enforcement~* Willing and able to withdraw and refrain from specific therapies (ask PI)~* Use medically acceptable form of contraception (female only)~* Signed informed consent~Exclusion Criteria:~* Significant traumatic brain injury~* Severe depression~* Bipolar and psychotic disorders~* Increase risk of suicide~* Significant clinical (cardiac, systemic infection, drug/alcohol abuse) or laboratory abnormalities (including positivity for Hep B, Hep C, HIV)~* Unable to wash-out specific medications (ask PI)~* History of violent behavior within past 2 years, unrelated to work duties~* History of drug or alcohol abuse within past 6 months~* Positive illegal substance test~* Known hypersensitivity to cyclobenzaprine~* Others: seizure disorders, uncontrolled sleep apnea, BMI\>40~* Participation in an investigational study in past 30 days~* In the process of litigating for compensation for a psychiatric disorder~* Females that are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime.
- TNX-102 SL, 2.8 mg (Type: ACTIVE_COMPARATOR): 1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime.
- TNX-102 SL, 5.6 mg (Type: ACTIVE_COMPARATOR): 2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).